Top

Published in:

01-06-2018 | Progress in Hematology

The significance and application of vascular niche in the development and maintenance of hematopoietic stem cells

Author: Ryohichi Sugimura

Published in: International Journal of Hematology | Issue 6/2018

Abstract

Deriving hematopoietic stem cells (HSCs) from human pluripotent stem cells is one of major goals in stem cell and hematological research. To induce HSCs from human pluripotent stem cells, many attempts to mimic embryonic development through stepwise exposure to morphogens. HSCs arise from dorsal aorta of embryos then migrate and settle in the bone marrow. Development and maintenance of HSCs are controlled by the microenvironmental cues around the blood vessels (called vascular niche) through morphogens and cytokines. Vascular niche serves as a common mechanism from embryo development to life-long maintenance of HSCs. In this chapter, I discuss that how vascular niche regulates development and maintenance of HSCs and exemplify the role of vascular niche to exquisitely induce HSCs from human pluripotent stem cells.

Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505:327–34. https://doi.org/10.1038/nature12984.CrossRefPubMedPubMedCentral

Kiel MJ, et al. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121:1109–21. https://doi.org/10.1016/j.cell.2005.05.026.CrossRefPubMed

Kunisaki Y, et al. Arteriolar niches maintain haematopoietic stem cell quiescence. Nature. 2013;502:637–43. https://doi.org/10.1038/nature12612.CrossRefPubMedPubMedCentral

Omatsu Y, Seike M, Sugiyama T, Kume T, Nagasawa T. Foxc1 is a critical regulator of haematopoietic stem/progenitor cell niche formation. Nature. 2014;508:536–40. https://doi.org/10.1038/nature13071.CrossRefPubMed

Sugimura R. Bioengineering hematopoietic stem cell niche toward regenerative medicine. Adv Drug Deliv Rev. 2016;99:212–20. https://doi.org/10.1016/j.addr.2015.10.010.CrossRefPubMed

Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell. 1996;86:897–906.CrossRefPubMed

Ivanovs A, et al. Highly potent human hematopoietic stem cells first emerge in the intraembryonic aorta-gonad-mesonephros region. J Exp Med. 2011;208:2417–27. https://doi.org/10.1084/jem.20111688.CrossRefPubMedPubMedCentral

Ng ES, et al. Differentiation of human embryonic stem cells to HOXA + hemogenic vasculature that resembles the aorta-gonad-mesonephros. Nat Biotechnol. 2016;34:1168–79. https://doi.org/10.1038/nbt.3702.CrossRefPubMed

Gomes AC, et al. Hematopoietic stem cell niches produce lineage-instructive signals to control multipotent progenitor differentiation. Immunity. 2016;45:1219–31. https://doi.org/10.1016/j.immuni.2016.11.004.CrossRefPubMedCentral

10.

Fares I, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science. 2014;345:1509–12. https://doi.org/10.1126/science.1256337.CrossRefPubMedPubMedCentral

11.

Reinisch A, et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat Med. 2016;22:812–21. https://doi.org/10.1038/nm.4103.CrossRefPubMedPubMedCentral

12.

Sugimura R, et al. Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature. 2017. https://doi.org/10.1038/nature22370.PubMedPubMedCentralCrossRef

13.

Lis R, et al. Conversion of adult endothelium to immunocompetent haematopoietic stem cells. Nature. 2017. https://doi.org/10.1038/nature22326.CrossRefPubMedPubMedCentral

Title: The significance and application of vascular niche in the development and maintenance of hematopoietic stem cells
Author: Ryohichi Sugimura
Publication date: 01-06-2018
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 6/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-018-2450-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

The role of telomere binding molecules for normal and abnormal hematopoiesis

Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan

Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms

Guest editorial: Regulatory signaling in normal and abnormal hematopoiesis

Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan

10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer